Pelacarsen Drug Fails to Reduce Cardiovascular Events Despite Lowering Lp(a) in Trial

The Phase 3 Lp(a)HORIZON trial found that pelacarsen, a drug designed to lower lipoprotein(a) (Lp(a)) levels, did not reduce major adverse cardiovascular events over 4.7 years. While the drug successfully lowered Lp(a), the primary endpoint was not met, indicating it did not translate to improved heart disease outcomes for patients with existing conditions. The findings were published in the New England Journal of Medicine.